STDE yields 2000000.00% · ABBV yields 3.06%● Live data
📍 STDE pulled ahead of the other in Year 1
Combined, STDE + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of STDE + ABBV for your $10,000?
Standard Energy Corporation engages in the acquisition of unproven oil and gas leaseholds with the intent of reselling or drilling; and developing such leaseholds with third-parties. It acquires primarily federal oil and gas leaseholds. The company also obtains leases through purchases in competitive bidding programs offered by various state agencies, principally the states of Utah and Wyoming. Standard Energy Corporation retains a royalty interest, ranging from 1% to 6% in various leaseholds that it resells. The company, through its wholly owned subsidiary, Petroleum Investment Company, also offers various geologic lease evaluation services; and provides information relating to geologic data, recommendations, and reports with respect to leaseholds offered in the leasing programs. Standard Energy Corporation also sells information with respect to individual oil and gas properties throughout the Rocky Mountain area, as well as offers oil and gas mapping services about properties located in the Rocky Mountain region. Further, it engages in the commercial development of its 'Biofuel Technologies', which are designed to solve the problem of disposing of municipal solid waste, through the recycle of the 'paper waste' in municipal waste into useful products, such as ethanol transportation fuels and fermentation lignin turbine fuels. The company was founded in 1978 and is headquartered in Salt Lake City, Utah.
Full STDE Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.